Navigation Links
Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
Date:8/30/2012

MOUNTAIN VIEW, Calif., Aug. 30, 2012 /PRNewswire/ -- A large competitor base and fluid market share has kept the research antibodies market highly competitive despite its maturity. Low entry barriers, large market size, and easy original equipment manufacturer (OEM) opportunities attract a wide variety of companies to this market. As research antibodies vary in quality by company, type, and even lot, customer satisfaction is hard to achieve. This translates to considerable chances for suppliers to capture market shares if they develop higher quality products.

New analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com) Strategic Analysis of the U.S. Research Antibodies Market research finds that the market earned revenues of $672.0 million in 2011 and estimates this to reach $775.0 million in 2016. This anticipated expansion is due to the high growth of various antibody-based technologies as well as the continued need for basic protein research.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Many technologies and applications that require antibodies come with their own set of dynamics and growth metrics. While some of these technologies continue to grow well, others have reached maturity and are in the process of phasing out. This results in a marketplace subject to a variety of growth factors, with surges in certain hot applications and research fields.

"Researchers use antibodies in a multitude of technologies that vary by age, popularity, ease-of-use, expense, throughput, and data output," said Frost & Sullivan Senior Industry Analyst Christi Bird. "These technologies enable applications in numerous research fields, tying growth in the research antibodies market to technology and application trends within the academic research and pharmaceutical communities."

Apart from a chaotic marketplace, the economic downturn since the end of 2008 has kept growth down to the low single digits. Consequent to the slowdown, budgetary concerns and inadequate government funding of biomedical research have made researchers cautious about their spending on laboratory products. Inflation levels in biomedical research are estimated to be around 3 percent, creating greater budget constraints for researchers each year. As the research antibodies market relies heavily on the academic sector, its growth will be greatly limited for the next two years.

Growth analyses of the top competitors in the market determined that suppliers are growing at varying rates and thus, market shares are likely to change considerably over the next five years. In addition, researchers' ranking of overall experience with suppliers differs greatly from the ranking of market shares, indicating substantial prospects for reputed suppliers.

"The competitive landscape of the market is expected to be very different in the next five years, with various companies growing much faster than the overall market," said Bird. "This points to pockets of growth and opportunities for well-positioned companies to be more successful in this market, driving growth beyond the overall market compound annual growth rate of 2.9 percent between 2011 and 2016."

Strategic Analysis of the U.S. Research Antibodies Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets:

  • Purchasing Trends in the Research Antibodies Market: Evaluating Budgets, Suppliers, and Unmet Needs
  • Frost & Sullivan 2011 Survey of Sequencing Technologies: Instrument Adoption on the Rise as Affordable Systems Enter the Market
  • Strategic Analysis of the U.S. Next-Generation Sequencing Services Market: A Convergence of Favorable Market Dynamics
  • Global Protein Purification Reagents Market: An Expanding Role in Biopharmaceutical; Diagnostics; and Basic Biomedical Research

All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Strategic Analysis of the U.S. Research Antibodies Market

NA8F-55

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ingenuity Systems Named 2013 World Economic Forum Technology Pioneer
2. Frost & Sullivan Lauds U-Systems for Its Unique Technology and Strategic Excellence Paving the Way for Robust Growth
3. Manhattan Isotope Technology Completes Drug Master File With Food and Drug Administration
4. Manhattan Isotope Technology Completes Drug Master File With Federal Drug Administration
5. Interventional Spine Announces its 75th Patient Treated with the PerX360 Percutaneous Spinal Fusion Technology
6. Cancer Patients in Central Vietnam to Gain Access to Advanced Radiotherapy Treatments Using Technology from Varian Medical Systems
7. Frost & Sullivan Lauds MobileHelp for Its Outstanding Products and Performance in the North American Health Technology Market
8. Microsemis New Packaging Technology Enables Miniaturized Implantable Medical Devices
9. Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patients Bedside In Less Than An Hour
10. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
11. Global Chiral Technology Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... analysis identified the highest gene Replikin Counts in Zika history back to 1946 (1). ...
(Date:5/5/2016)... May 5, 2016  Endo International plc (NASDAQ: ... that Brian Lortie , President, U.S. Branded ... position upon the appointment of a successor. Mr. ... U.S. Pharmaceuticals business with responsibility for all strategic, ... strategy and portfolio development, commercial operations, managed markets, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... While the ... being paid to the impact our aging population has on communities and resources. Aging ... adults plan for and face age-related challenges. , Aging Life Care is a ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... long-acting injectables (LAIs), today announced a development collaboration with the Australian critical ... serious mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic ...
(Date:5/5/2016)... ... 05, 2016 , ... Textile Exchange is excited to announce the ... review. The stakeholder review is an important opportunity for interested parties to give input ... to the wool industry., The RWS is intended to be a global benchmark for ...
Breaking Medicine News(10 mins):